Evaluation of the Efficacy of Chloroquine and Hydroxychloroquine in the Treatment of Individuals with COVID-19: A Systematic Review

被引:0
作者
Mendes, L. C. [1 ]
Avila, J. [1 ]
Pereira, A. A. [1 ]
机构
[1] Univ Fed Uberlandia, Fac Elect Engn, Ctr Innovat & Technol Assessment Hlth NIATS, Ave Joao Naves de Avila, BR-2121 Uberlandia, MG, Brazil
来源
XXVII BRAZILIAN CONGRESS ON BIOMEDICAL ENGINEERING, CBEB 2020 | 2022年
关键词
Chloroquine; Hydroxychloroquine; COVID-19; Clinical trial; Patients;
D O I
10.1007/978-3-030-70601-2_308
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
This work consists of a literature review that aims to evaluate the effects and efficacy of two drugs used to treat individuals with COVID-19: chloroquine (CQ) and hydroxychloroquine (HCQ). Both drugs have demonstrated antiviral activity against the new coronavirus in in vitro tests. However, there is currently no strong evidence from well-designed controlled studies of COVID-19 therapies tested in humans. In addition, the evidence on the effects of drugs on patients is extremely limited. The search for evidence was made from five chosen databases, and after applying the criteria for inclusion and exclusion of articles, 5 publications were obtained, which represented the basis for the construction of this work. We concluded that, in relation to CQ, no favorable outcomes were found in relation to its use. High doses of this drug can increase lethality due to the prolongation of the QT interval, and lower doses could not estimate evident benefits in infected patients. Assessing the results of HCQ, it can be concluded that more studies are needed to effectively use this drug in the treatment of individuals with COVID-19.
引用
收藏
页码:2111 / 2116
页数:6
相关论文
共 15 条
[1]  
Borba M, 2020, medRxiv, DOI [10.1101/2020.04.07.20056424, 10.1101/2020.04.07.20056424, DOI 10.1101/2020.04.07.20056424]
[2]  
CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI [10.15585/mmwr.mm6912e2, 10.15585/mmwr.mm6915e4]
[3]  
Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
[4]   Empirical studies of agile software development:: A systematic review [J].
Dyba, Tore ;
Dingsoyr, Torgeir .
INFORMATION AND SOFTWARE TECHNOLOGY, 2008, 50 (9-10) :833-859
[5]  
Esposito Silvano, 2020, Infez Med, V28, P198
[6]  
Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI [10.1016/j.ijantimicag.2020.105949, 10.1016/j.ijantimicag.2020.106063]
[7]   Old and re-purposed drugs for the treatment of COVID-19 [J].
Jean, Shio-Shin ;
Hsueh, Po-Ren .
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2020, 18 (09) :843-847
[8]  
Kapoor KM, 2020, ROLE CHLOROQUINE HYD, V2020
[9]  
Mahévas M, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1844, 10.1136/bmj.m2328]
[10]   Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis [J].
Rodriguez-Morales, Alfonso J. ;
Cardona-Ospina, Jaime A. ;
Gutierrez-Ocampo, Estefania ;
Villamizar-Pena, Rhuvi ;
Holguin-Rivera, Yeimer ;
Pablo Escalera-Antezana, Juan ;
Elena Alvarado-Arnez, Lucia ;
Bonilla-Aldana, D. Katterine ;
Franco-Paredes, Carlos ;
Henao-Martinez, Andres F. ;
Paniz-Mondolfi, Alberto ;
Lagos-Grisales, Guillermo J. ;
Ramirez-Vallejo, Eduardo ;
Suarez, Jose A. ;
Zambrano, Lysien, I ;
Villamil-Gomez, Wilmer E. ;
Balbin-Ramon, Graciela J. ;
Rabaan, Ali A. ;
Harapan, Harapan ;
Dhama, Kuldeep ;
Nishiura, Hiroshi ;
Kataoka, Hiromitsu ;
Ahmad, Tauseef ;
Sah, Ranjit .
TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2020, 34